Evaluation of Prognostic Factors in Anti-MDA5 Antibody-Positive Patients in Chongqing, China: A Retrospective Study

Figures & data

Table 1 Comparison of Demographic Data, Clinical Symptoms and Physical Signs Between Death and Survival Groups

	Death (n=10)	Survival (n=46)	p-value
Gender (female/male)	4/6	24/22	0.364
Onset age (years), median (25%, 75%)	59.50 (51.75, 63.00)	39.25 (49.00, 63.00)	0.022*
BMI, median (25%, 75%)	23.13 (19.90, 24.47)	22.12 (19.40, 24.70)	0.814
Disease duration (months), median (25%, 75%)	2 (1, 5)	3 (1, 12)	0.275
Smoke, n (%)	3 (30.0%)	16 (34.8%)	0.542
Clinical symptom
Fever, n (%)	2 (20.0%)	8 (17.4%)	0.576
Cough, n (%)	9 (90.0%)	26 (56.5%)	0.047*
Expectoration, n (%)	7 (70.0%)	20 (43.5%)	0.120
Dyspnea, n (%)	6 (60.0%)	18 (39.1%)	0.196

Note: *p-value was less than 0.05.

Abbreviation: BMI, Body mass index.

Table 2 Comparison of Laboratory Examinations Between Death and Survival Groups

	Death, Median (25%, 75%)	Survival, Median (25%, 75%)	p-value
RBC (cell/μL)	3975 (3685, 4300)	4270 (3885, 4585)	0.168
Hemoglobin (g/L)	121 (103, 132)	123 (107, 136)	0.622
WBC (cell/μL)	5795 (4268, 11,280)	5660 (4000, 7495)	0.448
PLT (cell/mL)	194 (148, 241)	184 (137, 227)	0.797
Neutrophil (cell/μL)	4890 (2895, 8940)	3790 (3023, 5383)	0.223
Lymphocyte	555 (493, 920)	1095 (640, 1480)	0.018*
Ferritin	1226.20 (649.28, 1500.00)	452.35 (231.30, 855.00)	0.021*
ESR (mm/1st hour)	60 (51, 82)	40 (19, 66)	0.039*
LDH (U/L)	352(331, 411)	259 (194, 331)	0.004*
CRP (mg/L)	16.16 (6.37, 65.99)	7.40 (5.00, 20.85)	0.158
Fib (g/L)	5.01 (3.52, 6.25)	4.47 (3.53, 5.62)	0.435
D-Dimer (mg/L)	0.20 (0.10, 0.38)	0.20 (0.10, 0.31)	0.956
Albumin (g/L)	29.70 (28.30, 31.48)	34.30 (30.73, 39.93)	0.009*
CK (U/L)	75.50 (34.08, 139.00)	55.00 (33.00, 197.25)	0.873
CK-MB (U/L)	16.30 (12.23, 22.40)	11.50 (8.73, 16.35)	0.093
IgG (g/L)	12.49 (8.25,15.94)	13.86 (11.50, 17.67)	0.294
IgM (g/L)	1.13 (0.79,1.52)	1.47 (1.15, 1.96)	0.102

Note: *p-value was less than 0.05.

Abbreviations: RBC, red blood cell; WBC, white blood cell; PLT, platelet; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; CRP, C-reactive protein; Fib, fibrinogen; CK, creatine kinase; CK-MB, creatine kinase isoenzyme MB; IgG, immunoglobulin G; IgM, immunoglobulin M.

Table 3 Comparison of High-Resolution Computed Tomography Manifestations Between Death and Survival Groups

	Death (n=10), n (%)	Survival (n=46), n (%)	p-value
Honey-combed shadow	0	5 (10.8%)	/
Reticle-like shadow	6 (60.0%)	12 (26.1%)	0.060
Patchy shadows	8 (80.0%)	24 (52.2%)	0.162
GGO	7 (70.0%)	15 (32.6%)	0.038*
Pleural effusion	3 (30.0%)	5 (10.8%)	0.143
Pleural adhesion	5 (30.0%)	7 (15.2%)	0.028*
Pleural thickening	8 (80.0%)	21 (45.7%)	0.080
Lymphadenectasis of mediastinum	6 (80.0%)	15 (32.6%)	0.152

Note: *p-value was less than 0.05.

Abbreviation: GGO, ground-glass opacity.

Table 4 Comparison of Diagnoses and Treatments Between Death and Survival Groups

	Death (n=10)	Survival (n=46)	p-value
IPAF, n (%)	7 (70.0%)	6 (13.0%)	0.001*
DM, n (%)	3 (30.0%)	29 (63.0%)	0.080
RA, n (%)	0	5 (10.8%)	/
pSS, n (%)	0	3 (6.5%)	/
SLE, n (%)	0	1 (2.2%)	/
SSc, n (%)	0	1 (2.2%)	/
Other, n (%)	0	1 (2.2%)	/
Treatment
Daily maximum MP dose (mg), median (25%, 75%)	160 (80, 625)	48 (40, 115)	0.028*
Tacrolimus or cyclosporin A, n (%)	2 (20.0%)	10 (21.7%)	0.990
IVCY, n (%)	9 (90.0%)	22 (47.8%)	0.031*
IVIG, n (%)	8 (80.0%)	12 (26.1%)	0.002*

Note: *p-value was less than 0.05.

Abbreviations: IPAF, interstitial pneumonia with autoimmune features; DM, dermatomyositis; RA, rheumatoid arthritis; pSS, primary sjogren's syndrome; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; MP, methylprednisolone; IVCY, intravenous cyclophosphamide; IVIG, intravenous immunoglobulin.